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In this prospective case series study, we consider the different factors between death and survival
groups of organophosphate poisoning. Patients in tertiary-care medical center who had been exposed
to organophosphate were included in the study. Pralidoxime (PAM) was discontinued after
atropine had controlled the clinical situation. We recorded the demographic data, amount of
organophosphate consumption, duration of coma, duration of ventilator use, duration of hospi-
talization, findings of chest X-ray, white blood cell count, acetylcholinesterase concentration,
plasma cholinesterase concentration, total atropine amount, duration of atropine use, total PAM
amount, duration of PAM use, urine organophosphate peak concentration, duration of urine
organophosphate and mortality rate. Urine was collected every 8 hours and was analyzed by gas
chromatography equipped with a flame photometric detector and gas chromatography with mass
spectrometer detector for organophosphate determination. The urine organophosphate peak
concentration was recorded. Wilcoxon rank sum test was used to compare the factors between death
and survival groups. Fisher’s exact test was used to compare the different findings of chest X-ray
between the death and survival groups. Evidently, the death group had a higher amount of
organophosphate consumption, duration of coma, and higher white blood cell count than those in
the survival group. Also, the death group had lower duration of hospitalization, and decreased
concentrations of acetylcholinesterase and plasma cholinesterase. Total PAM amount use and dura-
tion of PAM use were lower. However, the duration of ventilator use, findings of chest X-ray, total
atropine amount, duration of atropine, urine organophosphate peak concentration and duration of
urine organophosphate were similar in both groups. The mortality rate of our 50 cases was 20%. As
stated earlier, the cases of the death group had insufficient PAM therapy. The maximum duration of
PAM use was shorter than the maximum duration of urine organophosphate, although the medi-
ans of duration of PAM use were more than the medians of duration of urine organophosphate in
both the survival and death groups. Prolonged coma duration, lower level of acetylcholinesterase
and lower level of plasma cholinesterase were related to the poor prognosis of the patients.
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Organophosphates are widely used in agriculture.
Reports from the National Poison Control Center of
Taiwan indicate that organophosphate poisoning is
the leading cause of poisoning [1]. The main types of
poisoning are acute cholinergic crisis, intermediate
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syndrome and delayed neuropathy [2,3]. Atropine
and pralidoxime (PAM) are common antidotes used
in Taiwan.
The action of PAM is to activate acetylcholinesterase
by releasing acetylcholinesterase from acetylcho-
linesterase–organophosphate complex. It reduces the
amount of atropine required [4,5]. It also modulates
the nicotinic and central nervous system effects of
organophosphates [6]. A report in the literature shows
that organophosphate poisoning symptoms could reap-
pear later following 1-day treatment with an oxime.
The authors concluded that lipid-soluble and highly
protein-bound organophosphates were retained in
the tissues and their release later resulted in the reap-
pearance of the symptoms of poisoning [4]. In our
clinical presumption, the duration of atropine and
PAM therapy should cover the reappearance of the
symptoms of poisoning because of the release of
organophosphate from the tissue. We collected urine
containing organophosphate to ascertain whether the
duration of PAM use can cover the duration of urine
organophosphate in the same way as it covers the
release of organophosphate from the tissue.
Some authors reported that serum cholinesterase
concentration did not correlate with the total atropine
amount used. In the acute phase of organophosphate
poisoning, low serum acetylcholinesterase supports
the diagnosis of organophosphate poisoning but it
does not show a significant relationship with the sever-
ity of poisoning [7]. Serum cholinesterase levels have
no prognostic value in acute organophosphate poison-
ing according to Nouira et al [8]. However, Brahmi et al
reported that the marked decrease in acetylcholines-
terase activity appears as a prognostic factor in acute
organophosphate poisoning [9]. We compared the dif-
ferent factors including acetylcholinesterase concentra-
tion and plasma cholinesterase concentration between
death and survival groups of organophosphate poison-
ing to determine the prognostic factors.
MATERIALS AND METHODS
Clinical data collection
Organophosphate poisoning cases over a 2-year pe-
riod were included in this study at Taichung Veterans
General Hospital. The exact name of the organophos-
phate was determined. The demographic data, amount
of organophosphate consumption, duration of coma,
duration of hospitalization, duration of ventilator use,
findings of chest X-ray, white blood cell count, acetyl-
cholinesterase concentration, plasma cholinesterase
concentration, total atropine amount use, duration 
of atropine use, total PAM amount use, duration of
PAM use, urine organophosphate peak concentration,
duration of urine organophosphate and the cause of
mortality were recorded. The patient was first treated
with atropine (50 μg/hour, keeping heart rate [HR] 
at 80–120 beats/minute) and PAM (0.5 g/hour contin-
uous intravenous drip) until the symptoms subsided.
If heart rate decreased or the rale/rhonchi of breathing
sound increased, we increased atropine dosage and
allowed the heart rate to reach not more than 120
beats/minute. If sudden onset of detrimental condi-
tion developed, bolus atropine was used. When the
breathing sound was clear, atropine was tapered off
and then discontinued. If there was no reappearance
of symptoms, PAM was then discontinued.
Urine was collected from the patient every 8 hours
and 10mL was saved at –20°C in a freezer. It was then
detected by gas chromatography equipped with a
flame photometric detector (GC/FPD) and gas chro-
matography with mass spectrometer detector (GC/MS)
for organophosphate determination. Then urine organ-
ophosphate peak concentration was recorded.
Urine samples analysis
Organophosphate pesticide preparations
A 5 mL sample of urine was added to 1 g of sodium
chloride, mixed thoroughly, and extracted twice with
5 mL of methylene chloride. The extracts were com-
bined and dried through Na2SO4 and evaporated to
dryness. The residue was then dissolved in 0.5 mL of
acetone [10].
Instrument
A Hewlett Packard 5890 series II GC/FDP was used
for all measurements in organophosphate analysis. 
A DB-608 capillary column (30 m × 0.53 mm ID) was
used. The column temperature was kept at 180°C for
10 minutes. Operation conditions were as follows:
injection port temperature at 240°C, detector temper-
ature at 250°C, carrier gas (N2) flow rate of 10 mL/
minute, H2 flow rate of 75 mL/minute and air flow
rate of 100 mL/minute. The organophosphates were
identified by GC/MS. An HP-5MS capillary column
(30 m × 0.25 mm ID) was used. The column tempera-
ture was kept at 60°C for 2 minutes and 30°C/minute
to 270°C for 10 minutes. Solvent delay was 3 minutes.
Operation conditions were injection port temperature
at 220°C, detector temperature at 280°C, carrier gas
(He) flow rate at 1.0 mL/minute and electron impact
at 70 eV.
Quantitative analysis
The quantitativeness of biologic samples was exam-
ined using GC/FPD. The detection limits in urine
were 0.003 (o-ethyl-o-(4-nitrophenyl)-phenylphospho-
nothioate [EPN], parathion-methyl), 0.004 (demeton-S-
methyl), 0.01 (acephate, methamidophos, mevinphos),
0.02 (diazinon, monocrotophos, parathion-ethyl) and
0.03 (chlorpyrifos, dimethoate, dipterex, ethion, feni-
trothion, profenofos, phorate, prothiofos) μg/mL,
respectively, at a signal to noise ratio of 3 (limit 
of quantitation, LOQ). The recovery range of 17
organophosphate pesticides at concentrations of 0.25,
0.5 and 1.0 μg/mL was 80.38% to 103.7% from spiked
urine. Within-run study (n = 5) of urine samples
spiked with 0.25 μg/mL of 17 organophosphate pes-
ticides gave the range of coefficients of variation (CV)
from 0.76% to 7.08%.
Data description analysis
Due to small case numbers and nonparametric data,
Wilcoxon rank sum test was used to compare the
median data of the death and survival groups. Fisher’s
exact test was used to compare the different findings
of chest X-ray between the death and survival groups.
RESULTS
Table 1 shows the list of organophosphates in the 50
patients. Table 2 compares the data between the 40
survivors and the 10 dead. Thus, from the data in
Table 2, the death group had a higher amount of
organophosphate consumption, duration of coma
and white blood cell count than those in the survival
group. However, the findings of chest X-ray, duration
of ventilator use, total atropine amount, duration of
atropine, urine organophosphate peak concentration
and duration of urine organophosphate were similar
in both groups. The mortality rate was 20%. The rea-
sons for death were cardiac arrest (6 cases), septic
shock with aspiration pneumonia (2 cases), intractable
pulmonary edema (1 case), and cardiogenic shock 
(1 case).
DISCUSSION
There are significant differences between the death and
survival groups in their amount of organophosphate
consumption, duration of coma, duration of hospital-
ization, white blood cell count, concentrations of ace-
tylcholinesterase and plasma cholinesterase, total PAM
amount, and duration of PAM use as shown in Table 2.
The death group had a relatively higher amount of
organophosphate consumption, although there were
variable chemical structures as shown in Table 1. Pre-
dicted mortality was not significantly different from
Glasgow coma scales reported by Bilgin et al [11].
Duration of coma was significantly higher in the death
group of this study. Prolonged coma duration was
related to death. However, we should treat and cure
the patients intensively in spite of coma, because the
maximum duration of coma in the survival group
was up to 20 days.
Mechanical ventilators were required by patients
because of bronchial secretions, altered conscious level,
pneumonia, flaccid paralysis and intermediate syn-
drome [12]. The indications for mechanical ventilator
were encountered in each group. Mortality follow-
ing organophosphate poisoning remains high despite
adequate respiratory support, intensive care and spe-
cific therapy with atropine and oximes [13]. The du-
ration of ventilator use was not different for both the
groups of this study. The duration of ventilator use was
not a prognostic factor in organophosphate poisoning.
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Table 1. List of organophosphates
Organophosphate n
EPN 4
Dipterex 1
Diazinon 1
Dimethoate 2
Parathion-ethyl 2
Parathion-methyl 1
Profenofos 1
Monocrotophos 2
Mevinphos 10
Chlorpyrifos 3
Prothiofos 1
Ethion 1
Dimeton-S-methyl 1
Methamidophos 17
Phorate 1
Fenitrothion 1
Acephate 1
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Table 2. Comparisons between the death and survival groups
Deaths (n = 10) Survivals (n = 40) p
Age (yr) 0.8938
Median 49 46
Min–max 20–76 16–77
Sex 0.2770
Male 5 28
Female 5 12
Amount of organophosphate consumption 0.0171*
Median 275 80
Min–max 150–500 30–500
Unknown 6 15
White blood cell count (/mm3) 0.0169*
Median 20,900 13,900
Min–max 8,200–28,700 3,200–25,000
Chest X-ray 0.051
Pulmonary edema 4 17 Fisher’s
Pneumonia 4 4 exact
Normal 2 19
Duration of coma (27 cases) (d) 0.0062†
Median 2 0
Min–max 1–29 0–20
Duration of ventilator use (32 cases) (d) 0.1834
Median 2.5 1.5
Min–max 1–29 0–30
Duration of hospitalization (d) 0.0139*
Median 2.5 8
Min–max 1–29 2–50
Acetylcholinesterase concentration (U/L) 0.0031†
Median 2,471 4,281
Min–max 600–4,093 1,287–10,644
Plasma cholinesterase concentration (U/L) 0.0079†
Median 1,375 2,455
Min–max 500–4,608 937–8,663
Total atropine amount use (mg) 0.2297
Median 4.02 2.53
Min–max 1.20–38.71 0–137.63
Duration of atropine use (d) 0.9513
Median 2.5 3
Min–max 1–29 0–28
Total PAM amount use (g) 0.0428*
Median 15.5 47.5
Min–max 2–168 2–167.5
Duration of PAM use (d) 0.0382*
Median 2.5 5.5
Min–max 1–15 1–15
Urine organophosphate peak 
concentration (ppm) 0.1235
Median 118 1.26
Min–max 0.01–671.98 0.02–2,318.47
Duration of urine organophosphate (d) 0.7181
Median 2 3
Min–max 1–17 1–13
*p < 0.05 (Wilcoxon rank sum test); †p < 0.01 (Wilcoxon rank sum test). Min = minimum; max = maximum; PAM = pralidoxime.
One-third of subjects needing mechanical ventilation
and reaching intensive care units die within the first
72 hours of poisoning [13]. The duration of hospital
stay was shorter in the death group than in the sur-
vival group of this study. The seven of the 10 deaths
were caused by cardiogenic reasons. The reason was
why the duration of hospital stay was shorter, but the
duration of ventilator use was not related to death.
White blood cell count was elevated in the death
group, which may be related to inflammation and
lung infection. One cause of death was due to aspira-
tion pneumonia. Aygun et al reported that low 
serum acetylcholinesterase supports the diagnosis of
organophosphate poisoning but this does not show a
significant relationship to the severity of poisoning.
There was no significant difference between the first-
day serum acetylcholinesterase of the patients with
severe poisoning and of the patients with mild poison-
ing [7]. However, Brahmi et al reported that marked
decrease in acetylcholinesterase activity appears as
the prognostic factor in acute organophosphate poi-
soning [9]. There were lower concentrations of acetyl-
cholinesterase and plasma cholinesterase in the death
group than in the survival group of this study. These
two factors were related to the clinical outcome of the
patients in this study.
Because of the phenomenon of aging, oxime treat-
ment must be started as early as possible after exposure,
ideally within 5 minutes to 2 hours. Traditionally, a
patient is treated with PAM for 1–2 days [5]. As a
result, physicians are unable to treat seriously ill
organophosphate poisoning patients with long-term
treatment of PAM and have to use more atropine. This
also indirectly lengthens the patient’s hospital stay and
affects the rate of recovery. The lipid-soluble and highly
protein-bound organophosphates remaining in the tis-
sues would cause reappearance of toxic and clinical
symptoms [5]. PAM therapy should cover the reap-
pearance of organophosphate from tissue and clini-
cal symptoms. It is impossible to completely recover
and prevent reappearance of symptoms with a 3-day
PAM regimen. In this study, the maximum duration
of PAM use was 15 days and the maximum duration of
urine organophosphate was 17 days (Table 2), although
the medians of duration of PAM use were more than
the medians of duration of urine organophosphate in
both the survival and death groups.
Atropine dosing should be titrated to the therapeu-
tic end point of the clearing of respiratory secretions
and the cessation of bronchoconstriction [14]. Atropine
had beneficial effects on the heart rate, prolonged the
time before the heart rate declined, and delayed death
in a rat study [15]. In this study, death was mainly
caused by cardiogenic deterioration. The total atropine
amount use in the death group showed no difference
from that in the survival group. Whether we augment
atropine amount and duration of atropine use and set
up the higher increase of heart rate range (for example
90–130 beats/minute), it can result in early decrease of
bronchial secretion and lower mortality. Further con-
trolled study is needed to verify this.
Clinical treatment with atropine and PAM should
be continued until symptoms cease. If this is not
done, there will be a detrimental effect on those
patients whose urine organophosphate remains posi-
tive for longer periods of time and whose organo-
phosphate concentrations are high. The death group
had a greater amount of organophosphate consump-
tion and a lesser total PAM amount use than that of the
survival group. The median of total PAM amount use
was 15.5 g and the median of the duration of PAM use
was 2.5 days. The cases of the death group may have
had insufficient PAM therapy compared with the max-
imum of PAM 12 g/day (500 mg/hour) [16]. Aggres-
sively increasing the amount of PAM was suggested in
the death group of this study. However, in a new meta-
analysis of clinical trials, oximes were not effective in
the management of organophosphate-poisoned pa-
tients and, surprisingly, they can be dangerous and
worsen the patient’s clinical situation. More research
is needed to define the effect of PAM therapy [17].
Animal experiments show that organophosphates
are detected in urine and feces from 24 hours to 
3–4 days. Experimental oral administration of several
other pesticides to human volunteers has shown that
when urinary metabolites are measured, the rate of
elimination is similar to that seen in animal studies. It
appears that 90% of the compound is eliminated in
between 6 and 24 hours after administration. There is
evidence, however, that after self-poisoning, patients
may still be excreting detectable urine levels of metabo-
lites up to 14 days later [18]. This study determines
the length of time in which organophosphates can be
detected in the urine, which represents the relative
length of time that organophosphates are retained in
the body. When humans attempt suicide, they may
take larger amounts of the poison and so urine sam-
ples remain positive for longer periods of time than
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those of animals. In this study, the urine organophos-
phate peak concentration and duration of urine or-
ganophosphate were not definitely related to death
under PAM and atropine therapy. However, the
longest duration of detectable urine was 17 days and
its highest concentration was 2,318.5 mg/mL (Table
2). The maximum durations of atropine use and of
PAM use were 29 days and 15 days, respectively. In our
clinical judgment, PAM and atropine therapy should
cover the reappearance of organophosphate released
from the tissue.
As shown in Table 2, our mortality rate for 50 cases
was 20%. The reasons for death were cardiac arrest (6
cases), septic shock with aspiration pneumonia (2
cases), intractable pulmonary edema (1 case) and car-
diogenic shock (1 case). Singh et al reported that the
mortality rate of 18 patients with organophosphate
poisoning was 22% [19]. The causes of death were
intractable pulmonary edema (2 cases), cardiac arrhy-
thmia (1 case) and aspiration pneumonia (1 case).
Yamashita et al reported a mortality of 25% (32/130).
The causes of death were delay in discovery and trans-
port (18 cases), insufficient respiratory management 
(8 cases) and severe underlying or co-existing diseases
(6 cases) [20]. We had a higher rate of cardiac arrest
(6/10). Yamashita et al reported delay in discovery
and transport (18/32). There might also have been
delay in discovery of transient cardiac arrhythmia in
this study with only cardiac arrest recorded. We had a
similar mortality rate to the other reports.
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